Factors underlying sensitivity of cancers to small-molecule kinase inhibitors - PubMed (original) (raw)

Review

doi: 10.1038/nrd2871. Epub 2009 Jul 24.

Affiliations

Review

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Pasi A Jänne et al. Nat Rev Drug Discov. 2009 Sep.

Abstract

Selective small-molecule kinase inhibitors have emerged over the past decade as an important class of anti-cancer agents, and have demonstrated impressive clinical efficacy in several different diseases, including relatively common malignancies such as breast and lung cancer. However, clinical benefit is typically limited to a fraction of treated patients. Genomic features of individual tumours contribute significantly to such clinical responses, and these seem to vary tremendously across patients. Additional factors, including pharmacogenomics, the tumour microenvironment and rapidly acquired drug resistance, also contribute to the clinical sensitivity of various cancers, and should be considered and applied in the development and use of new kinase inhibitors.

PubMed Disclaimer

References

    1. Mol Cancer Ther. 2008 Nov;7(11):3499-508 - PubMed
    1. Cancer Res. 2006 Jun 1;66(11):5542-8 - PubMed
    1. Mol Cell Biol. 2004 Aug;24(16):7275-83 - PubMed
    1. Cancer Res. 2008 Apr 1;68(7):2340-8 - PubMed
    1. Br J Cancer. 2006 Oct 23;95(8):998-1004 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources